Bcl-2: The pendulum of the cell fate

Journal of Experimental and Clinical Cancer Research

Volumn 16, Issue 1, 1997, Pages 3-10

  Blandino, G ^a   Strano, S ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

apoptotic pathway; bcl 2

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; CANCER; CANCER THERAPY; CELL PROLIFERATION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; CARRIER PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HOMEODOMAIN PROTEINS; HUMANS; LYMPHOMA, FOLLICULAR; MEMBRANE PROTEINS; MICE; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REPLICATION PROTEIN C; REPRESSOR PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TRANSCRIPTION FACTORS;

EID: 0030933092     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Tsujimoto Y., Cossman J., Jaffe E., Croce C.: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985.
2. Tsujimoto Y., Croce C.M.: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA. 83: 5214-5218, 1986.
3. Tsujimoto Y., Louie E., Bashir M.M., Croce C.M.: The reciprocal partners of both the t(14;18) and t(11;14) translocations involved in B-cell neoplasms are rearranged by the same mechanisms. Oncogene 2: 347-351, 1988.
4. Fukuhara S., Rowley J.D., Varrakojis D., Golomb H.M.: Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Research 39: 3119-3123, 1979.
5. Yunis J.J., Frizzera G., Oken M.M., McKenna J., Theologides A., Arnensen M.: Multiple recurrent genomic defects in follicular lymphoma. N. Engl. J. Med. 316: 79-85, 1987.
6. Tsujimoto Y., Gorham J., Cossman J., Jaffe E., Croce C.M.: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390-1393, 1985.
7. Bakhshi A., Jensen J.P., Goldman P., Wrigth J.J., McBride O.W., Epstein A.L., Korsmeyer S.J:. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on chromosome 18. Cell 41: 899-906, 1985.
8. Nowell P.C., and Croce C.M.: Cytogenetics of neoplasia. In Development and Recognition of the Transformed Cell. M.I. Greene and T. Hamaoka, editors. Plenum Publishing Corporation. New York.
9. Cleary M.L., Galili N., Sklar J.: Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J. Exp. Med. 164: 315-320, 1986.
10. Seto M., Jaeger U., Hockett R.D., Graninger W., Bennett S., Goldman P., Korsmeyer S.J.: Alternative promoters and exons, somatic mutation and transcriptional deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 7: 123-131, 1988.
11. Cleary M.L., Smith S.D., Sklar J.: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47: 19-26, 1986.
12. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
13. Chen-Levy Z., Nourse J., Cleary M.L.: The bcl-2 candidate proto oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) traslocation. Mol. Cell. Biol. 9: 701-706, 1989.
14. Chen-Levy S. and Cleary M.L.: Membrane topology of the bcl-2 proto oncogenic protein demonstrated in vitro. J. Biol. Chem. 265: 4929-4933, 1990.
15. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., and Reed J.C.: Investigations of the subcellular distribution of the BCL-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mithocondrial membranes. Cancer Research 53: 4701-4714, 1993.
16. Hockembery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer SJ.: Bcl-2 is an inner mithocondrial membrane protein that blocks programmed cell death. Nature (Lond.) 348: 334-336, 1990.
17. Monaghan P., Robertson D., Amos A.S., Dyer M.J.S., Mason D.Y., and Greaves M.F.: Ultrastructural localization of bcl-2 protein. J. Histochem. Cytochem. 40: 1819-1825, 1992.
18. Jacobson M.D., Burne J.F., King M.P., Miyashita T., Reed J.C., Raff M.C.: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365-369, 1993.
19. Buttke T.M. and Sandstrom P.A.: Oxidative stress as a mediator of apoptosis. Immunol. Today 15: 7-10, 1994.
20. Hockenbery D.M., Oltvai Z.N., Yin X-M., Milliman C.L., Korsmeyer S.J.: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251, 1993.
21. Kane D.J., Sarafian T.A., Anton R., Hahan H., Gralla E.B., Valentine J.S., Ord T., Bredesen D.E. Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species. Science. 262: 1274-1277, 1993.
22. Greenlund L.J.S, Deckwerth T.L and Johnson E.M.J.: Superoxide dismutase delays neuronal apoptosis: a role for reactive oxgen species in programmed neuronal death. Neuron 14: 303-315, 1995.
23. Martinou J.C., Dubois-Dauphin M.; Staple J.K., Rodriguez I., Frankowski H., Missotten M., Albertini P., Talabot D., Catsicas S., Pietra C., Huarte J.: Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 13: 1017-1030, 1994.
24. Kinouchi H., Epstein C.J., Mizui T., Carlson E., Chen S.F., and Chaan P.H.: Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc. Natl. Acad. Sci. USA 11158-11162, 1991.
25. Davies A.M.: The bcl-2 family of proteins, and the regulation of neuronal survival. Trends Nurosci. 18: 355-358, 1995.
26. Hockenbery D., Zutter M., Hickey W., Nahm M., Korsmeyer S.J.: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA 88: 6961-6965, 1991.
27. Pezzella F., Tse A.G., Cordell J.L., Pulford K.A.F., Guter K.C., Mason R.Y.: Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosome translocation. Am. J. Path. 137: 225-228, 1990.
28. Kormayer S.: Bcl-2 initiates a new category of oncogenes: regulator of cell death. Blood. 80: 879-886, 1992.
29. Williams G.T., Smith C.A.: Molecular regulation of apoptosis: Genetic controls on cell death. Cell 74: 777-779, 1993.
30. Boise L.H., Gonzales-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., and Thompson C.: Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic death. Cell 74: 597-608, 1993.
31. Oltvai Z.N., Milliman C.L. and Korsmeyer S.: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
32. Kozopas K.M., Yang T., Buchan H.L., Zhou P., and Craig R.W.: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc. Natl. Acad. Sci. USA 90: 3516-3520, 1993.
33. Lin E.Y., Orlofsky A., Berger M.S., and Prystowsky M.B.: Characterization of Al, a novel haemopoietic-specific early response gene with sequence similarity to bcl-2. J. Immunol. 151: 1979-1988, 1993.
34. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., and Korsmeyer S.: Bad, a heterodimeric partner for Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
35. Chittenden T., Harrington E.A., O'Connor R., Flemington C., Lutz R.J., Evan G.I., and Guild B.C.: Induction of apoptosis by the Bcl-2 homologue Bak. Nature (London) 374: 733-736, 1995.
36. Farrow S.N., White J.H.M., Martinou I., Raven T., Pun K.T., Grinham C.J. Martinou J.C. and Brown R.: Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19k. Nature (London) 374: 731-733, 1995.
37. Kiefer M.C., Brauer M.J., Powers V.C., Wu J.J., Umansky S.R., Tomei L.D. and Barr P.J.: Modulation of apoptosis by the widely distributed Bcl 2 homologue Bak. Nature (London) 374: 736-739, 1995.
38. Takayama S., Sato T., Krajewski S., Kockel K., Irie S., Millan J.A., Reed J.C.: Cloning and functional analysis of BAG-1: A novel bcl-2 binding protein with anti-cell death activity. Cell. 80: 279-288, 1995.
39. Nguyen M., Millar D.G., Yong V.W, Korsmeyer S.J., Shore G.C.: Targeting of bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J. Biol. Chem. 268: 2565-2568, 1993.
40. Tanaka S., Saito K. and Reed J.C.: Structure-function analysis of the bcl-2 oncoprotein. J. Biol. Chem. 268: 10920-10926, 1993.
41. L is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 120: 3033-3042, 1994.
42. Yang E., and Korsmeeyer S.: Molecular Thanatopsis: A discourse on the BCL2 family and cell death. Blood. Vol. 88, No 2: 386-401, 1996.
43. Knudson C.M., Tung K., Brown G. and Karsmeyer S.J.: Bax deficient mice demonstrate lymphoid hyperplasia but male germ cell death (1995).
44. Yin X.M., Oltvai Z.N. and Korsmeyer SJ.: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369: 321-323, 1994.
45. Reynolds J.E., Yang T., Qian L., Jenkinson J.D., Eastman A., Craig R.W.: Mcl-1, a member of the bcl-2 family, delays apoptosis induced by c myc overexpression in Chinese hamster ovary cells. Cancer Res. 64: 6348-6352, 1994.
46. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell. Biol. 124: 1-6, 1994
47. Reed J.C.: Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North. Am. 9: 451-474, 1995.
48. Furuya Y., Krajewski S., Epstein J.I., Reed J.C., Isaacs J.T.: Enhanced expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 11: 321-326, 1993.
49. Shabaik A.S., Krajewski S., Burgan A., Krajewska M., Reed J.C.: BCL-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J. Urol. Pathol. 3: 17-27, 1994.
50. Bronner M., Culin C., Reed J.C., Furth E.E.: BCL-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am. J. Pathol. 146: 20-26, 1995.
51. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Hoffman B., Lieberman D., Reed J.C.: Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
52. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C.M.: Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54: 2095-2097, 1994.
53. Young R.L. and Korsmeyer S.: A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Molecular and Cellular Biology 13: 3686-3697, 1993.
54. Miyashita T., Harigai M., Hanada M., Reed J.C.: Identification of a p53 dependent negative response element in the bcl-2 gene. Cancer Res. 54: 3131-3135, 1994.
55. Blandino et al. unpublished observations.
56. Strasser A., Harris A.W., Jacks T., Cory S.: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79: 329-339, 1994.
57. Miyashita T., Reed J.C.: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell. 80: 293-299, 1995.
58. Selvakumaran M., Lin H-K., Miyashita T., Wang H.G., Krajewski S., Reed J.C., Hoffman B., Lieberman D.: Immediate early up-regulation of bax expression by p53 but not TGFb1: a paradigm for distinct apoptotic pathways. Oncogene. 9: 1791-1798, 1994.
59. Zhan Q., Fan S., Bae I., Guillouf C., Liebermann D.A., O'Connor P.M., Fornace A.J. Jr.: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 9: 3743-3751, 1994.
60. Chen M., Quintans J., Fuks Z., Thompson C., Kufe D.W., Weichselbaum R.R.: Suppression of bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor a, and ceramide. Cancer Res. 55: 991-994, 1995.
61. Miyashita T., and Reed J.C.: Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemoterapeutic drugs. Cancer Res. 52: 5407-5411, 1992.
62. Miyashita T., and Reed J.C.: Bcl-2 oncoprotein blocks chemoterapy induced apoptosis in a human leukemia cell line. Blood. 81: 151-157, 1993.
63. Walton W.I., Whysong P.M., O'Connor D., Hockenbery D., Korsmeyer S.J., and Kohn K.W.: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53: 1853-1861, 1993.
64. Reed J.C., Kitada S., Takayama S., Miyashita T.: Regulation of chemioresistance by the bcl-2 oncoprotein in non-Hodking's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol. 5: S61, 1994.
65. Reed J.C., Miyashita T., Takayama S., Wang H-G., Sato T., Krajewski S., Aimé-Sempé C., Bodrug S., Kitada S., and Hanada M.: Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. Journal of Cellular Biochemistry. 60: 23-32, 1996.
66. Lotem J., and Sachs L.: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and-defective myeloid leukemic cells. Cell Growth E Diff. 4: 41-47, 1993.
67. Campos L., Sabido O., Rouault J-P., Guyotat D.: Effects of bcl-2 antisense oligonucleotides on in vitro proliferation and survival of normal marrow progenitors and leukaemic cells. Blood. 84: 595-600, 1994.
68. Reed J., Haldar S., Cuddy M., Croce C.M., Makover D.: Bcl-2-mediated tumorigenicity in a T-lymphoid cell line: synergy with c-myc and inhibition by bcl-2 antisense. Proc. Natl. Acad. Sci. USA 87: 3660-3664, 1990.
69. Kitada S., Miyashita T., Tanaka S., Reed J.C.: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev. 3: 157-169, 1993.
70. Kitada S., Takayama S., DeRiel K., Tanaka S., Reed J.C.: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 4: 71-79, 1994.
71. Reed J., Stein C., Haldar S., Subasinghe C., Croce C., Yum S., Cohen J.: Antisense-mediated inhibition of bcl-2 proto-oncogene expression and leukemic cell growth: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 50: 6565-6570, 1990.
72. Texeira C., Reed J.C., Pratt M.A.C.: Estrogen promotes chemoterapeutic drug resistance by a mechanism involving BCL-2 protooncogene expression in human breast cancer cells. Cancer Res. 55: 3902-3907, 1995.
73. Berchem G.J., Bosseler M., Sugars L.Y., Voeller H.J., Zeitlin S., Gelmann E.P.: Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 55: 735-738, 1995.
74. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C.: p53 mutations in human cancers. Science 253: 49-53, 1991.
75. Kastan M.B., Onkywere O., Sidransky D., Vogelstein B., and Craig R.W.: Participation of p53 in the cellular response to DNA damage. Cancer Res. 51: 6304-6311, 1991.
76. Gottlieb T.M., and Oren M.: p53 in growth control and neoplasia. Biochem. Biophys. Acta. 1287: 77-102, 1996.